These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Efficacy of renin-angiotensin system inhibitors for patients with heart failure with preserved ejection fraction and mild to moderate chronic kidney disease. Tsujimoto T, Kajio H. Eur J Prev Cardiol; 2018 Aug; 25(12):1268-1277. PubMed ID: 29808753 [Abstract] [Full Text] [Related]
10. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Heitner JF, Lewis EF, O'Meara E, Rouleau JL, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, McKinlay SM, Pitt B. Circulation; 2015 Jan 06; 131(1):34-42. PubMed ID: 25406305 [Abstract] [Full Text] [Related]
15. Perturbations in serum chloride homeostasis in heart failure with preserved ejection fraction: insights from TOPCAT. Grodin JL, Testani JM, Pandey A, Sambandam K, Drazner MH, Fang JC, Tang WHW. Eur J Heart Fail; 2018 Oct 06; 20(10):1436-1443. PubMed ID: 29893446 [Abstract] [Full Text] [Related]
16. Designing Future Clinical Trials in Heart Failure With Preserved Ejection Fraction: Lessons From TOPCAT. Patel RB, Shah SJ, Fonarow GC, Butler J, Vaduganathan M. Curr Heart Fail Rep; 2017 Aug 06; 14(4):217-222. PubMed ID: 28647918 [Abstract] [Full Text] [Related]
17. Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spironolactone. Cohen JB, Schrauben SJ, Zhao L, Basso MD, Cvijic ME, Li Z, Yarde M, Wang Z, Bhattacharya PT, Chirinos DA, Prenner S, Zamani P, Seiffert DA, Car BD, Gordon DA, Margulies K, Cappola T, Chirinos JA. JACC Heart Fail; 2020 Mar 06; 8(3):172-184. PubMed ID: 31926856 [Abstract] [Full Text] [Related]
18. Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. Shah AM, Claggett B, Sweitzer NK, Shah SJ, Anand IS, Liu L, Pitt B, Pfeffer MA, Solomon SD. Circulation; 2015 Aug 04; 132(5):402-14. PubMed ID: 26130119 [Abstract] [Full Text] [Related]
19. QRS Duration Is a Predictor of Adverse Outcomes in Heart Failure With Preserved Ejection Fraction. Joseph J, Claggett BC, Anand IS, Fleg JL, Huynh T, Desai AS, Solomon SD, O'Meara E, Mckinlay S, Pitt B, Pfeffer MA, Lewis EF. JACC Heart Fail; 2016 Jun 04; 4(6):477-86. PubMed ID: 27039126 [Abstract] [Full Text] [Related]
20. Spironolactone for Management of Heart Failure with Preserved Ejection Fraction: Whither to After TOPCAT? Mitter SS, Shah SJ. Curr Atheroscler Rep; 2015 Nov 04; 17(11):64. PubMed ID: 26408016 [Abstract] [Full Text] [Related] Page: [Next] [New Search]